{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:41:20Z","timestamp":1786977680757,"version":"build-2736575974"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":1918,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Duchenne muscular dystrophy (DMD) is an X-linked inherited disease due to dystrophin deficiency causing skeletal and cardiac muscle dysfunction. Affected patients lose ambulation by age 12 and usually die in the second to third decades of life from cardiac and respiratory failure. Symptomatic treatment includes the use of anti-inflammatory corticosteroids, which are associated with side effects including weight gain, osteoporosis, and increased risk of cardiovascular disease. Novel treatment options include blockade of the renin\u2013angiotensin\u2013aldosterone system, because angiotensin as well as aldosterone contribute to persistent inflammation and fibrosis, and aldosterone blockade represents an efficacious anti-fibrotic approach in cardiac failure. Recent preclinical findings enabled successful clinical testing of a combination of steroidal mineralocorticoid receptor antagonists (MRAs) and angiotensin converting enzyme inhibitors in DMD boys. The efficacy of MRAs alone on dystrophic skeletal muscle and heart has not been investigated. Here, we tested efficacy of the novel non-steroidal MRA finerenone as a monotherapy in a preclinical DMD model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The dystrophin-deficient, utrophin haploinsufficient mouse model of DMD was treated with finerenone and compared with untreated dystrophic and wild-type controls. Grip strength, electrocardiography, cardiac magnetic resonance imaging, muscle force measurements, histological quantification, and gene expression studies were performed. Finerenone treatment alone resulted in significant improvements in clinically relevant functional parameters in both skeletal muscle and heart. Normalized grip strength in rested dystrophic mice treated with finerenone (40.3 \u00b1 1.0 mN\/g) was significantly higher (P = 0.0182) compared with untreated dystrophic mice (35.2 \u00b1 1.5 mN\/g). Fatigued finerenone-treated dystrophic mice showed an even greater relative improvement (P = 0.0003) in normalized grip strength (37.5 \u00b1 1.1 mN\/g) compared with untreated mice (29.7 \u00b1 1.1 mN\/g). Finerenone treatment also led to significantly lower (P = 0.0075) susceptibility to limb muscle damage characteristic of DMD measured during a contraction-induced injury protocol. Normalized limb muscle force after five lengthening contractions resulted in retention of 71 \u00b1 7% of baseline force in finerenone-treated compared with only 51 \u00b1 4% in untreated dystrophic mice. Finerenone treatment also prevented significant reductions in myocardial strain rate (P = 0.0409), the earliest sign of DMD cardiomyopathy. Moreover, treatment with finerenone led to very specific cardiac gene expression changes in clock genes that might modify cardiac pathophysiology in this DMD model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Finerenone administered as a monotherapy is disease modifying for both skeletal muscle and heart in a preclinical DMD model. These findings support further evaluation of finerenone in DMD clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12996","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T09:35:34Z","timestamp":1600421734000},"page":"3983-3995","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mineralocorticoid Receptor Antagonism by Finerenone is Sufficient to Improve Function in Preclinical Muscular Dystrophy"],"prefix":"10.1093","volume":"7","author":[{"given":"Jeovanna","family":"Lowe","sequence":"first","affiliation":[{"name":"Department of Physiology and Cell Biology, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-7528","authenticated-orcid":false,"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[{"name":"R&D Preclinical Research Cardiovascular, Bayer AG , Wuppertal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Haupt","sequence":"additional","affiliation":[{"name":"Department of Physiology and Cell Biology, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra K.","family":"Peczkowski","sequence":"additional","affiliation":[{"name":"Department of Physiology and Cell Biology, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Department of Physiology and Cell Biology, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Spencer","family":"Hauck","sequence":"additional","affiliation":[{"name":"Department of Physiology and Cell Biology, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feni K.","family":"Kadakia","sequence":"additional","affiliation":[{"name":"Department of Physiology and Cell Biology, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Zins","sequence":"additional","affiliation":[{"name":"Department of Physiology and Cell Biology, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierce C.","family":"Ciccone","sequence":"additional","affiliation":[{"name":"Department of Physiology and Cell Biology, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Smart","sequence":"additional","affiliation":[{"name":"Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sandner","sequence":"additional","affiliation":[{"name":"R&D Preclinical Research Cardiovascular, Bayer AG , Wuppertal ,","place":["Germany"]},{"name":"Department of Pharmacology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subha V.","family":"Raman","sequence":"additional","affiliation":[{"name":"Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.L.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Physiology and Cell Biology, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3239-8530","authenticated-orcid":false,"given":"Jill A.","family":"Rafael-Fortney","sequence":"additional","affiliation":[{"name":"Department of Physiology and Cell Biology, College of Medicine, The Ohio State University , Columbus, OH, 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"2026012115030485400_ehf212996-bib-0001","volume-title":"Duchenne Muscular Dystrophy","author":"Emery","year":"1993","edition":"Second"},{"key":"2026012115030485400_ehf212996-bib-0002","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","article-title":"The pathogenesis and therapy of muscular dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"2026012115030485400_ehf212996-bib-0003","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"key":"2026012115030485400_ehf212996-bib-0004","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"2026012115030485400_ehf212996-bib-0005","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology"},{"key":"2026012115030485400_ehf212996-bib-0006","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"2026012115030485400_ehf212996-bib-0007","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cct.2017.04.008","article-title":"Developing standardized corticosteroid treatment for Duchenne muscular dystrophy","volume":"58","author":"Guglieri","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"2026012115030485400_ehf212996-bib-0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088360","article-title":"Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy","volume":"9","author":"Janssen","year":"2014","journal-title":"PLoS ONE"},{"key":"2026012115030485400_ehf212996-bib-0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034204","article-title":"Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse","volume":"7","author":"Sali","year":"2012","journal-title":"PLoS ONE"},{"key":"2026012115030485400_ehf212996-bib-0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/eurjhf\/hfp028","article-title":"Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse of dystrophin-deficient cardiomyopathy","volume":"11","author":"Bauer","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026012115030485400_ehf212996-bib-0011","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ahj.2007.05.014","article-title":"Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up","volume":"154","author":"Duboc","year":"2007","journal-title":"Am Heart J"},{"key":"2026012115030485400_ehf212996-bib-0012","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1532-429X-13-60","article-title":"Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance","volume":"13","author":"Hor","year":"2011","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026012115030485400_ehf212996-bib-0013","doi-asserted-by":"crossref","first-page":"C155","DOI":"10.1152\/ajpcell.00269.2016","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles","volume":"312","author":"Chadwick","year":"2017","journal-title":"Am J Physiol Cell Physiol"},{"key":"2026012115030485400_ehf212996-bib-0014","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JND-160173","article-title":"Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice","volume":"3","author":"Lowe","year":"2016","journal-title":"J Neuromusc Diseases"},{"key":"2026012115030485400_ehf212996-bib-0015","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1161\/CIRCULATIONAHA.111.031716","article-title":"Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice","volume":"124","author":"Rafael-Fortney","year":"2011","journal-title":"Circulation"},{"key":"2026012115030485400_ehf212996-bib-0016","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JND-150099","article-title":"The angiotensin converting enzyme inhibitor lisinopril improves muscle histopathology but not contractile function in a mouse model of Duchenne muscular dystrophy","volume":"2","author":"Lowe","year":"2015","journal-title":"J Neuromusc Diseases"},{"key":"2026012115030485400_ehf212996-bib-0017","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1096\/fj.15-276782","article-title":"Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target","volume":"29","author":"Chadwick","year":"2015","journal-title":"FASEB J"},{"key":"2026012115030485400_ehf212996-bib-0018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1677\/JME-09-0031","article-title":"The mineralocorticoid receptor and its coregulators","volume":"43","author":"Yang","year":"2009","journal-title":"J Mol Endocrinol"},{"key":"2026012115030485400_ehf212996-bib-0019","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2026012115030485400_ehf212996-bib-0020","first-page":"5167","article-title":"Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy","volume":"25","author":"Chadwick","year":"2016","journal-title":"Hum Mol Genet"},{"key":"2026012115030485400_ehf212996-bib-0021","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Raman","year":"2015","journal-title":"Lancet Neurol"},{"key":"2026012115030485400_ehf212996-bib-0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13023-017-0590-8","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial","volume":"12","author":"Raman","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2026012115030485400_ehf212996-bib-0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013501","article-title":"Stabilization of early Duchenne cardiomyopathy with aldosterone inhibition: results of the multicenter AIDMD trial","volume":"8","author":"Raman","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026012115030485400_ehf212996-bib-0024","first-page":"2030","article-title":"Mineralocorticoid receptor antagonists improve membrane integrity independent of muscle force in muscular dystrophy","volume":"28","author":"Hauck","year":"2019","journal-title":"Hum Mol Genet"},{"key":"2026012115030485400_ehf212996-bib-0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012115030485400_ehf212996-bib-0026","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026012115030485400_ehf212996-bib-0027","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115030485400_ehf212996-bib-0028","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MNH.0000000000000340","article-title":"Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease","volume":"26","author":"Dojki","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026012115030485400_ehf212996-bib-0029","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026012115030485400_ehf212996-bib-0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","article-title":"Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences","volume":"27","author":"Yang","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"2026012115030485400_ehf212996-bib-0031","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2026012115030485400_ehf212996-bib-0032","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012115030485400_ehf212996-bib-0033","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"2026012115030485400_ehf212996-bib-0034","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/eurheartj\/eht235","article-title":"The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?","volume":"34","author":"Bauersachs","year":"2013","journal-title":"Eur Heart J"},{"key":"2026012115030485400_ehf212996-bib-0035","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/eurheartj\/ehw155","article-title":"Finerenone in heart failure: walking a fine line","volume":"37","author":"Naegele","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115030485400_ehf212996-bib-0036","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0960-8966(98)00048-0","article-title":"Consequences of the combined deficiency in dystrophin and utrophin on the mechanical properties and myosin composition of some limb and respiratory muscles of the mouse","volume":"8","author":"Deconinck","year":"1998","journal-title":"Neuromuscul Disord"},{"key":"2026012115030485400_ehf212996-bib-0037","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"2026012115030485400_ehf212996-bib-0038","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3233\/JND-180323","article-title":"Mineralocorticoid receptor antagonists in muscular dystrophy mice during aging and exercise","volume":"5","author":"Lowe","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"2026012115030485400_ehf212996-bib-0039","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1152\/physiolgenomics.00128.2016","article-title":"Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle","volume":"49","author":"Chadwick","year":"2017","journal-title":"Physiol Genomics"},{"key":"2026012115030485400_ehf212996-bib-0040","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1165\/rcmb.2003-0370OC","article-title":"Matrix metalloproteinase-9-deficient dendritic cells have impaired migration through tracheal epithelial tight junctions","volume":"30","author":"Ichiyasu","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012115030485400_ehf212996-bib-0041","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","article-title":"Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function","volume":"57","author":"Lother","year":"2011","journal-title":"Hypertension"},{"key":"2026012115030485400_ehf212996-bib-0042","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau9685","article-title":"Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice","volume":"12","author":"Oakley","year":"2019","journal-title":"Sci Signal"},{"key":"2026012115030485400_ehf212996-bib-0043","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00246-014-0972-9","article-title":"Regional circumferential strain is a biomarker for disease severity in duchenne muscular dystrophy heart disease: a cross-sectional study","volume":"36","author":"Hor","year":"2015","journal-title":"Pediatr Cardiol"},{"key":"2026012115030485400_ehf212996-bib-0044","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jacc.2008.12.032","article-title":"Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study","volume":"53","author":"Hor","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026012115030485400_ehf212996-bib-0045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nmd.2015.01.005","article-title":"Renal function in children and adolescents with Duchenne muscular dystrophy","volume":"25","author":"Braat","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"2026012115030485400_ehf212996-bib-0046","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/mus.21420","article-title":"Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy","volume":"40","author":"Viollet","year":"2009","journal-title":"Muscle Nerve"},{"key":"2026012115030485400_ehf212996-bib-0047","article-title":"Isometric and eccentric force generation assessment of skeletal muscles isolated from murine models of muscular dystrophies","volume":"31","author":"Moorwood","year":"2013","journal-title":"J Vis Exp"},{"key":"2026012115030485400_ehf212996-bib-0048","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0092-8674(00)80532-2","article-title":"Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy","volume":"90","author":"Deconinck","year":"1997","journal-title":"Cell"},{"key":"2026012115030485400_ehf212996-bib-0049","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/dom.13393","article-title":"Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction","volume":"20","author":"Lachaux","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026012115030485400_ehf212996-bib-0050","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1074248416636477","article-title":"Nicorandil, a nitric oxide donor and ATP-sensitive potassium channel opener, protects against dystrophin-deficient cardiomyopathy","volume":"21","author":"Afzal","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026012115030485400_ehf212996-bib-0051","doi-asserted-by":"crossref","first-page":"H1969","DOI":"10.1152\/ajpheart.00489.2007","article-title":"The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice","volume":"293","author":"Williams","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026012115030485400_ehf212996-bib-0052","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1152\/ajpheart.00582.2005","article-title":"The circadian clock within the heart: potential influence on myocardial gene expression, metabolism, and function","volume":"290","author":"Young","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026012115030485400_ehf212996-bib-0053","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1210\/en.2016-1911","article-title":"Deoxycorticosterone\/salt-mediated cardiac inflammation and fibrosis are dependent on functional CLOCK signaling in male mice","volume":"158","author":"Fletcher","year":"2017","journal-title":"Endocrinology"},{"key":"2026012115030485400_ehf212996-bib-0054","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00380-006-0968-3","article-title":"Aldosterone induces circadian gene expression of clock genes in H9c2 cardiomyoblasts","volume":"22","author":"Tanaka","year":"2007","journal-title":"Heart Vessels"},{"key":"2026012115030485400_ehf212996-bib-0055","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J Clin Invest"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12996","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12996","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3983\/65902330\/eschf_7_6_3983.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3983\/65902330\/eschf_7_6_3983.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:03:31Z","timestamp":1769025811000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/6\/3983\/8372501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,9,18]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12996","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"2020-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}